
Ask a doctor about a prescription for Axocar
Ezetimibe + Simvastatin
Axocar contains the active substances ezetimibe and simvastatin. Axocar is a medicine used to
reduce the level of total cholesterol, "bad" cholesterol (LDL cholesterol) and fatty substances called
triglycerides in the blood. Additionally, Axocar increases the level of "good" cholesterol (HDL cholesterol).
Axocar works through 2 mechanisms that reduce cholesterol levels. The active substance ezetimibe reduces
the absorption of cholesterol in the digestive tract. The active substance simvastatin, belonging to a class
of medicines called "statins", inhibits the production of cholesterol in the body.
Cholesterol is one of several fatty substances present in the blood. Total cholesterol consists mainly of
LDL cholesterol and HDL cholesterol.
LDL cholesterol is often called "bad" cholesterol because it can accumulate on the walls of arteries, forming
plaques that can eventually cause narrowing of the arteries, limiting or blocking blood flow to vital organs,
such as the heart and brain. Blocking blood flow can lead to a heart attack or stroke.
HDL cholesterol is often called "good" cholesterol because it helps prevent the accumulation of bad cholesterol
in the arteries and protects against heart disease.
Triglycerides are another type of fat present in the blood that can contribute to the increased risk of developing
heart disease.
Axocar is used in patients for whom diet alone is not sufficient to control cholesterol levels. During treatment
with this medicine, a cholesterol-lowering diet should be followed.
Axocar is used as a supplementary measure to a cholesterol-lowering diet in cases of:
Axocar does not affect weight loss.
In case of doubt about taking any of the above-mentioned medicines, consult a doctor.
Before starting treatment with Axocar, inform your doctor:
The doctor should perform a blood test before starting treatment with Axocar and during treatment if the patient has any liver problems. The purpose of the test is to assess liver function.
The doctor may also perform blood tests to assess liver function after starting treatment with Axocar.
During therapy, the doctor will closely monitor the patient's health if they have diabetes or are at risk of developing diabetes. The risk of developing diabetes is higher in people who have high blood sugar and fat levels, are overweight, and have high blood pressure.
Avoid taking Axocar and fibrates (certain cholesterol-lowering medicines) at the same time, as there is no data on the simultaneous use of Axocar and fibrates.
Axocar is not recommended for children under 10 years of age.
Tell your doctor or pharmacist about all medicines the patient is taking or has recently taken, as well as any medicines they plan to take, including those containing the following active substances. Taking Axocar with any of the following medicines may increase the risk of muscle problems (some of which are listed in the "Do not take Axocar" section):
Additional information on rhabdomyolysis can be found in section 4.
Tell your doctor or pharmacist about all medicines the patient has taken recently, including those available without a prescription. In particular, tell your doctor if the patient is taking any of the following:
Inform any doctor who prescribes a new medicine about taking Axocar.
Grapefruit juice contains one or more components that increase the metabolism of certain medicines, including Axocar. Grapefruit juice should be avoided, as it may increase the risk of muscle problems.
Do not take Axocar if pregnant, planning to become pregnant, or suspecting pregnancy. If the patient becomes pregnant while taking Axocar, they should stop taking the medicine and consult a doctor immediately. Do not take Axocar during breastfeeding, as it is not known whether the medicine passes into breast milk.
Consult a doctor or pharmacist before taking any medicine.
It is not expected that Axocar will affect driving or using machines. However, consider that some people may experience dizziness after taking Axocar.
Axocar contains lactose and sodium.
Axocar tablets contain a sugar called lactose. If the patient has been diagnosed with intolerance to some sugars, they should consult a doctor before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which means it is "sodium-free".
The doctor will determine the dose of Axocar suitable for the patient based on their current treatment and individual risk.
Take this medicine always as directed by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist.
Adults: the recommended dose is 1 tablet, taken orally, once a day.
Use in adolescents (10 to 17 years old): the recommended dose is 1 tablet, taken orally, once a day (do not exceed the maximum dose of 10 mg + 40 mg per day).
The dose of Axocar, 10 mg + 80 mg, is recommended only for adult patients with very high cholesterol levels and a high risk of heart disease, who have not achieved target cholesterol levels with lower doses of the medicine.
If optimal dosing cannot be achieved with Axocar, the doctor may prescribe other tablets containing ezetimibe with simvastatin.
The tablets do not have a dividing line and should not be divided.
Axocar should be taken in the evening. It can be taken with or without food.
If the doctor has prescribed Axocar and another cholesterol-lowering medicine containing the active substance colestyramine or another bile acid sequestrant, take Axocar at least 2 hours before or 4 hours after taking the bile acid sequestrant.
Consult a doctor or pharmacist.
Do not take a double dose to make up for a missed dose; take the usual dose of Axocar the next day at the usual time
Consult a doctor or pharmacist, as cholesterol levels may rise again.
If you have any further doubts about taking this medicine, consult a doctor or pharmacist.
Like all medicines, Axocar can cause side effects, although not everybody gets them (see section 2).
The following side effects have been reported commonly(may affect up to 1 in 10 people):
The following side effects have been reported uncommonly(may affect up to 1 in 100 people):
The following side effects have been reported rarely(may affect up to 1 in 1,000 people):
The following side effects have been reported very rarely(may affect up to 1 in 10,000 people):
The following side effects have been reported with an unknown frequency(frequency cannot be estimated from the available data) in patients taking both ezetimibe and simvastatin combination and ezetimibe or simvastatin:
Additional possible side effects reported in patients taking some statins:
death has occurred.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181 C
02 222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can be reported to the marketing authorization holder or its representative in Poland.
Reporting side effects will help gather more information on the safety of this medicine.
Store the medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and packaging after "EXP".
The expiry date refers to the last day of the month.
Do not store above 25°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substances of Axocar are ezetimibe and simvastatin.
Each tablet contains 10 mg of ezetimibe and 10 mg of simvastatin.
Each tablet contains 10 mg of ezetimibe and 20 mg of simvastatin.
Each tablet contains 10 mg of ezetimibe and 40 mg of simvastatin.
Each tablet contains 10 mg of ezetimibe and 80 mg of simvastatin.
Other ingredients are:
Core:lactose monohydrate, hypromellose, sodium croscarmellose, microcrystalline cellulose, ascorbic acid, citric acid, butylhydroxyanisole (BHA), propyl gallate, magnesium stearate.
Color mixture:lactose monohydrate, yellow iron oxide (E 172), red iron oxide (E 172), and black iron oxide (E 172).
Axocar, 10 mg+10 mg, are light brown, speckled, round tablets with a diameter of 6 mm, convex on both sides with the marking "511" on one side.
Axocar, 10 mg+20 mg, are light brown, speckled, round tablets with a diameter of 8 mm, convex on both sides with the marking "512" on one side.
Axocar, 10 mg+40 mg, are light brown, speckled, round tablets with a diameter of 10 mm, convex on both sides with the marking "513" on one side.
Axocar, 10 mg+80 mg, are light brown, speckled, capsule-shaped tablets with dimensions of 17.5x7.55 mm, convex on both sides with the marking "515" on one side.
Pack sizes
Blisters.
Axocar, 10 mg+10 mg: 10, 30, 50, 100, and 300 tablets.
Axocar, 10 mg+20 mg, 10 mg+40 mg, 10 mg+80 mg: 30, 50, 100, and 300 tablets.
Not all pack sizes may be marketed.
Zentiva, k.s., U kabelovny 130, Dolní Měcholupy, 102 37 Prague 10, Czech Republic
Balkanpharma-Dupnitsa AD, 3 Samokovsko Shosse Street, 2600 Dupnitsa, Bulgaria
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Denmark: Ezimvalla
Germany: Ezetimib Simvastatin
Italy: Ezetimibe e Simvastatina Zentiva
Portugal: Sinvastatina + Ezetimiba Zentiva
Slovakia: Cornusan
Poland : Axocar
Date of last revision of the leaflet:September 2021
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Axocar – subject to medical assessment and local rules.